Howard Capital Management Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

by · The Cerbat Gem

Howard Capital Management Inc. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,067 shares of the biopharmaceutical company’s stock after buying an additional 358 shares during the period. Howard Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,610,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Activest Wealth Management boosted its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $27,000. Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $32,000. Finally, SouthState Corp lifted its position in shares of Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REGN has been the topic of a number of analyst reports. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Jefferies Financial Group lifted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Sanford C. Bernstein lifted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Finally, BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $802.35.

Check Out Our Latest Stock Analysis on REGN

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $654.48 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $935.86. The company’s fifty day moving average price is $578.20 and its 200-day moving average price is $563.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market capitalization of $69.37 billion, a PE ratio of 16.49, a price-to-earnings-growth ratio of 1.82 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.46 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).